Current Report Filing (8-k)
19 Abril 2021 - 7:50AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): April 12, 2021
GLOBAL
WHOLEHEALTH PARTNERS CORPORATION
(Exact
name of registrant as specified in its charter)
|
Nevada
|
000-56035
|
46-2316220
|
(State
or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification No.)
|
|
1402 N El
Camino Real
San
Clemente, CA
|
92672
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Registrant's
telephone number, including area code (714) 392-9752
N/A
(Former name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
¨
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Section
1 - Registrant’s Business and Operations
Item
1.01 Entry into a Material Definitive Agreement.
On
April 12, 2021, Global Wholehealth Partners Corporation (the “Company”) entered into a Mutual Sales and Marketing
Agreement (“Agreement”) with Nunzia Pharmaceutical Inc. (“Nunzia”). Under the terms of the Agreement, each company has
mutual abilities to share their products for sell under nonexclusive but favorable conditions and prices. The duration of the agreement is for an initial period of five years commencing on April 12,
2021.
The
Company agreed to issue 5,000,000 shares of its restricted common stock to Nunzia and Nunzia agreed to issue 5,000,000 shares of its
restricted common stock to the Company.
A
copy of the agreement is furnished as Exhibit 10.1 to this Current Report on Form 8-K.
Section
9 – Financial Statement and Exhibits
Item 9.01 Financial Statements and Exhibits.
|
Exhibit No.
|
Document
|
Location
|
|
10.1
|
Mutual Sales and Marketing Agreement between Global Wholehealth Partners
Corporation and Nunzia Pharmaceutical Inc., dated April 12, 2021
|
Filed Herewith
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
GLOBAL
WHOLEHEALTH PARTNERS CORPORATION
(Registrant)
|
|
Date:
April 19, 2021
|
By:
/s/ Charles Strongo
Charles Strongo
Chief Executive Officer
|
Global Wholehealth Partn... (CE) (USOTC:GWHP)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Global Wholehealth Partn... (CE) (USOTC:GWHP)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
